Event of interest | Entry-first event | 1st - 2nd event | 2nd - 3rd event | 3rd - 4th event | ANY EVENT after surgery | |||||
---|---|---|---|---|---|---|---|---|---|---|
Gap time* (SD) | N (%) | Gap time (SD) | N (%) | Gap time (SD) | N (%) | Gap time (SD) | N (%) | Gap time (SD) | N (%) | |
Locoregional | 5.85 (3.60) | 134 (14.6%) | 2.57 (2.13) | 15 (4.4%) | 7.52 - | 1 (1.1%) | - - | 0 (0%) | 5.53 (3.60) | 150 (11.1%) |
Contralateral breast cancer | 5.60 (3.45) | 63 (6.9%) | 1.39 (1.54) | 6 (1.8%) | - - | 0 (0%) | - - | 0 (0%) | 5.23 (3.53) | 69 (5.1%) |
Metastases | 5.23 (3.29) | 117 (12.7%) | 1.14 (1.68) | 64 (18.9%) | 1.10 (1.48) | 7 (7.9%) | - - | 0 (0%) | 3.68 (3.42) | 188 (13.9%) |
2nd cancer other than breast | 4.71 (2.64) | 25 (2.7%) | 0.75 (0.71) | 3 (0.9%) | 1.71 (2.42) | 2 (2.3%) | - - | 0 (0%) | 4.12 (2.80) | 30 (2.2%) |
Death from cancer | 1.56 (.) | 1 (0.1%) | 2.14 (1.81) | 76 (22.4%) | 1.83 (1.62) | 52 (59.1%) | 1.21 (1.97) | 4 (40%) | 1.99 (1.71) | 133 (9.8%) |
Censoring** | 10.83 (2.31) | 580 (63.1%) | 3.41 (3.08) | 251 (74.0%) | 2.38 (2.20) | 78 (88.6%) | 1.47 (1.37) | 10 (100%) | 7.99 (4.51) | 919 (67.8%) |
TOTAL | 8.87 (3.78) | 919 (100%) | 2.89 (2.94) | 339 (100%) | 2.32 (2.22) | 88 (100%) | 1.47 (1.37) | 10 (100%) | 6.89 (4.51) | 1356 (100%) |